Media2022-08-02T10:30:37+02:00

Media

Press Releases

OncoOne at the 2022 AACR meeting
April 08, 2022

OncoOne Presents Preclinical Proof of Concept Data for its Next-Generation oxMIF-targeted Monoclonal Antibody ON203 at the AACR Annual Meeting.

read more
OncoOne & GenScript ProBio
November 17, 2021

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF.

read more
OncoOne establishes a U.S. subsidiary
September 13, 2021

OncoOne Appoints Brent Meadows as Chief Business Officer and establishes a U.S. subsidiary as base for strategic partnerships and business development activities.

read more
OncoOne Announces Initiation of IND‐Enabling Studies
June 10, 2021

OncoOne Announces Initiation of IND‐Enabling Studies for Lead Program Targeting Oxidized Macrophage Migration Inhibitory Factor and Secures EUR 1M to Explore Potential in Inflammatory Diseases.

read more
OncoOne – new Scientific Advisory Board
September 3, 2020

OncoOne is delighted to announce the formation of our new Scientific Advisory Board. This board will help shape and guide the strategy of OncoOne working closely with the leadership team.

read more
OncoOne Launches with EUR 13 Million Series
March 18, 2020

OncoOne Launches with EUR 13 Million Series A to Develop Multiple Drug Modalities for Unexplored Target.

read more

General News

OncoOne Newsletter Q2/2022
July, 2022

Another successful quarter in the books at OncoOne. Get more information about the Second Quarter 2022 Highlights and upcoming events of OncoOne.

OncoOne Newsletter Q1/2022
April, 2022

Et voilà: our first, quarterly newsletter including key achievements and upcoming events of OncoOne.

First academic thesis at OncoOne
May, 2021

The first academic thesis at OncoOne has been completed. Our team member, Gregor Rossmüller, conducted and successfully completed his master’s thesis at OncoOne. He graduated at the University of Natural Resources and Applied Life Sciences (BOKU), Vienna.

OncoOne moved laboratory & office
April, 2020

We moved our laboratory and office activities to the Vienna BioCenter. The head office remains in Klosterneuburg.

CEO at Golden Ribbon Run
May, 2019

Our CEO, Randolf Kerschbaumer represented OncoOne at this year’s Golden Ribbon Run in Klosterneuburg. The Golden Ribbon Run is all about drawing attention to the joint fight against childhood cancer and all the money raised will be donated to Kinderkrebshilfe, the representative for the interests of children and adolescents suffering from cancer and their families, in Austria.

OncoOne met Dr. Petra Buhoslav
March, 2019

We presented our startup, OncoOne to state councilor, Dr. Petra Bohuslav. We thank Dr. Bohuslav and the Accent Incubator for their interest in our research projects and for the great discussion!

OncoOne received a grant
November, 2018

OncoOne received a grant from the leading national funding agency for industrial research and development in Austria, The Austrian Research Promotion Agency (FFG).

OncoOne opened labs in Vienna
October, 2018

OncoOne opened our labs at the University of Natural Resources and Life Sciences, Vienna.

OncoOne received pre-seed funding
August, 2018

OncoOne received pre-seed funding from the Austria Wirtschaftsservice Gesellschaft (AWS).

OncoOne participates the incubator program
August, 2018

OncoOne was accepted by the Accent Incubator board to participate in the incubator program of Lower Austria.

The birthday of OncoOne
June, 2018

OncoOne was founded by Randolf Kerschbaumer, Michael Thiele and Alexander Schinagl.

New Hires

MSc Peter Wulz
June, 2022

OncoOne welcomed our new team member Peter Wulz, Director Regulatory and Quality Affairs. With over 20 years of experience in regulatory affairs & leadership in the pharma industry, Peter’s expertise is invaluable to us as we remain focused on rapidly progressing our lead oncology asset, ON203 toward the clinic.

Dr. Barbara Maurer & Dr. Maroua Ferhat
November, 2021

OncoOne welcomed our new team members Dr. Barbara Maurer, Scientist, and Dr. Maroua Ferhat, Scientist, who will support our Biology Group.

Dr. Sara Sajko & Mert Basaran
September, 2021

OncoOne welcomed our new team members Dr. Sara Sajko, Scientist and Mert Basaran, Research Associate, who will support our Biotechnology Group.

Dr. Christine Landlinger-Schubert
August, 2021

OncoOne welcomed Dr. Christine Landlinger-Schubert, Director Preclinical Development & Project Lead Inflammation who will oversee and manage non-clinical studies for our new biotherapeutics.

Friedmund Bachmann
April, 2021

OncoOne welcomed Friedmund Bachmann, our new Director of CMC Biologics, who will support us in manufacturing, analytics and quality control efforts.

Alejandro Puchol Tarazona
March, 2021

OncoOne welcomed our new Scientist, Alejandro Puchol Tarazona to the Biotechnology Group. Alejandro will support the protein engineering activities and protein production.

Verena Höld
September, 2020

We welcomed our new Research Associate, Verena Höld to our team. Verena will support our bioengineering and cell biology activities.

Maria Reitzinger
June, 2020

We welcomed our management assistant, Maria Reitzinger to the OncoOne team. Maria will support our CEO in all organisational and administrative tasks.

Julia Mayer
December, 2019

We welcomed our new Research Associate, Julia Mayer to the OncoOne team. Julia will support our cell biology activities.

Irina Mirkina
October, 2019

We welcomed Irina Mirkina to our team. Irina (Senior Scientist) will support bioengineering and cell biology activities.

.

Gregor Rossmüller
December, 2018

We would like to welcome Gregor Rossmüller to our team. Gregor will support us as Research Associate.

Scientific Conferences

World Conference of Lung Cancer, 2022
August 6-9, 2022

Meet our Director Preclinical Development, Christine Landlinger at the WCLC in Vienna, Austria. Be sure to visit Christine’s e-poster on August 8 to learn more about our clinical candidate for the treatment of malignant solid tumors (e-poster EP08.01-015 – Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti-oxMIF Antibody ON203 in Malignant Solid Tumors).

ESMO GI
June 29–July 2, 2022

Our Senior Scientist Barbara Maurer will attend the ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spain. Barbara will present data demonstrating antitumorigenic activity and TME modulation of ON203 in patient-derived colorectal cancer tumoroids.

Theranostics World Congress
June 24–26, 2022

Our Director CMC Biologics, Friedmund Bachmann will attend the 6th Theranostics World Congress in Wiesbaden, Germany. He will present a poster on ON102, our diagnostic radioimmunoconjugate targeting oxMIF.

EACR 2022
June 20–23, 2022

Meet our Director Preclinical Development, Christine Landlinger & Barbara Maurer, Senior Scientist at the EACR 2022 in Seville, Spain. Be sure to visit Barbara’s poster on ON203 to learn more about our clinical candidate for solid tumor indications.

World Congress on Inflammation
June 5–8, 2022

Meet our Director Preclinical Development & Project Lead Inflammation, Christine Landlinger & Maroua Ferhat, Research Scientist at the WCI22 in Rome. Be sure to visit Christine’s talk on our inflammation candidate ON104 to learn more.

ASCO 2022
June 3–7, 2022

Meet our CBO, Brent Meadows at the ASCO 2022 in Chicago to learn more about OncoOne’s novel therapies for the treatment of solid tumors and autoimmune diseases.

Immuno-Oncology Summit Europe
May 23–25, 2022

Our CSO, Michael Thiele will give a podium presentation entitled “Novel Therapeutic Antibodies Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF)” in the program “Targeting the Tumour Microenvironment” at the Immuno-Oncology Summit Europe.

PEGS Boston: The Essential Protein Engineering & Cell Therapy Summit
May 2–6, 2022

Our CSO, Michael Thiele will be leading a session entitled “A New Immunotherapy Target: Co-Development of a Therapeutic Antibody and a Radioimmune Diagnostic Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF)” at the PEGS, Boston, US.

12th Clinical Biomarker & CDx Summit Europe
April 27–28, 2022

OncoOne’s CEO Randolf Kerschbaumer will give a talk on “oxMIF as a novel biomarker and immuno-oncology therapeutic target for precision medicine”, at the 12th Clinical Biomarker & CDx Summit Europe; April 27–28, London, UK.

AACR Annual Meeting 2022
April 08–13, 2022

OncoOne will present its latest development for the treatment of solid tumors and lead candidate ON203 live at the AACR in New Orleans. Visit us at our poster presentation on Sunday, April 10th in Exhibit Halls D-H, Section 21, Poster # 313, and meet OncoOne’s CTO, Alexander Schinagl, CBO, Brent Meadows, and CEO, Randolf Kerschbaumer, in person.

Cambridge Healthtech Institute’s 9th Annual Immuno-Oncology Summit, Boston
October 4–6th, 2021

Meet our new CBO, Brent Meadows, at CHI’s 9th Annual Immuno-Oncology Summit in Boston to learn more about OncoOne’s pipeline of novel, anti-cancer therapies for the treatment of solid tumors and inflammation. Please visit OncoOne at poster #6 entitled “Harnessing oxidized macrophage migration inhibitory factor (oxMIF) as a druggable isoform of MIF for targeted anticancer therapies”.

To view the virtual poster presentation by OncoOne’s CSO, Michael Thiele, please click here.

PEGS summit Europe
November 12–16, 2018

Meet OncoOne’s Heads of External and Internal Research, Michael Thiele and Alexander Schinagl at the Protein & Antibody Engineering Summit in Lisbon, Portugal.

Partnering Conferences

BIO Asia-Taiwan
July 27–31, 2022

OncoOne’s CBO, Brent Meadows attended the BIO Asia-Taiwan to discuss our groundbreaking approach to targeting MIF.

BIO2022
June 13–16, 2022

OncoOne’s CEO, Randolf Kerschbaumer will be present at the BIO2022. Randolf will give a corporate presentation on June 15 at 4:45 PM PDT on our innovative oxMIF-targeting pipeline in oncology & immunology.

BIO Europe Spring digital event
March 28–31, 2022

Meet our CBO, Brent Meadows, CEO, Randolf Kerschbaumer, and CSO, Michael Thiele, at the digital BIO-Europe Spring 2022 to learn more about OncoOne’s novel therapies for the treatment of solid tumors and inflammatory/autoimmune diseases.

BIO CEO & Investors Conference, NYC
February 14th, 2022

Our CEO Randolf Kerschbaumer and our CBO Brent Meadows will attend in person at the hybrid 2022 BIO CEO & Investor Conference in NYC.
Randolf will present OncoOne’s corporate highlights and progress live at 10am EST on February 14th, 2022.

BIO-Europe Spring Digital Event
March 22–25, 2021

Meet our CEO, Randolf Kerschbaumer and CSO, Michael Thiele at the digital BIO-Europe Spring to learn more about OncoOne’s mission to develop novel, anti-cancer therapies for the treatment of solid tumors.

BIO-Europe Spring Digital Event
March 23–27, 2020

OncoOne’s CEO, Randolf Kerschbaumer and CSO, Michael Thiele will participate in the BIO-Europe Spring digital event.

BIO-Europe
November 11–13, 2019

OncoOne’s CEO, Randolf Kerschbaumer and COO, Michael Thiele will attend BIO-Europe in Hamburg, Germany.

3rd Drug Discovery Nexus Summit
May 23–24, 2019

Meet OncoOne’s CEO, Randolf Kerschbaumer at the 3rd Drug Discovery Nexus Summit in Munich, Germany.

BIO-Europe Spring
March 25–27, 2019

Meet OncoOne’s CEO, Randolf Kerschbaumer at the BIO-Europe Spring in Vienna, Austria.

Oncology Strategy Meeting Europe
March 13, 2019

Meet OncoOne’s CEO, Randolf Kerschbaumer at the Oncology Strategy Meeting Europe 2019 in Munich, Germany.

Social Media

Follow us on:

linkedin fb

Publications

  • Mitchell, R. A., Liao, H., Chesney, J., Fingerle-Rowsor, G., Baugh, J., David, J., & Bucala, R. (2002). Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proceedings of the National Academy of Sciences of the United States of America, 99(1), 345–350. https://doi.org/10.1073/PNAS.012511599
  • Calandra, T., & Roger, T. (2003). Macrophage migration inhibitory factor: a regulator of innate immunity. Nature Reviews Immunology, 3(10), 791–800. https://doi.org/10.1038/nri120
  • Roger, T., Schlapbach, L. J., Schneider, A., Weier, M., Wellmann, S., Marquis, P., Vermijlen, D., Sweep, F. C. G. J., Leng, L., Bucala, R., Calandra, T., & Giannoni, E. (2017). Plasma Levels of Macrophage Migration Inhibitory Factor and d-Dopachrome Tautomerase Show a Highly Specific Profile in Early Life. Frontiers in Immunology, 8(JAN), 25. https://doi.org/10.3389/FIMMU.2017.00026
  • Krockenberger, M., Kranke, P., Häusler, S., Engel, J. B., Horn, E., Nürnberger, K., Jörg, W., Dietl, J., & Hönig, A. (2012). Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis. Anticancer Research, 32(12), 5233–5238. https://ar.iiarjournals.org/content/32/12/5233
  • Thiele, M., Kerschbaumer, R. J., Tam, F. W. K., Völkel, D., Douillard, P., Schinagl, A., Kühnel, H., Smith, J., McDaid, J. P., Bhangal, G., Yu, M.-C., Pusey, C. D., Cook, H. T., Kovarik, J., Magelky, E., Bhan, A., Rieger, M., Mudde, G. C., Ehrlich, H., … Scheiflinger, F. (2015). Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions. The Journal of Immunology, 195(5), 2343–2352. https://doi.org/10.4049/jimmunol.1500572
  • Schinagl, A., Thiele, M., Douillard, P., Völkel, D., Kenner, L., Kazemi, Z., Freissmuth, M., Scheiflinger, F., & Kerschbaumer, R. J. (2016). Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer. Oncotarget, 7(45), 73486–73496. https://doi.org/10.18632/oncotarget.11970
Go to Top